[Update 2016 - Immunotherapy for urothelial carcinoma].
Dokumenttyp:
Journal Article; Review; Article
Autor(en):
Retz, M; Gschwend, J E; Schmid, S C
Abstract:
Advanced urothelial carcinoma of the bladder is an aggressive tumor with a poor prognosis. Besides surgical therapy, classical chemotherapy with platinum compounds is the mainstay of advanced bladder cancer treatment. In recent years, immune modulating therapies have come into the focus of clinical trials. This review provides an overview of the biological mechanisms and immuno-oncological drugs that are currently being analyzed in clinical trials as well as established standard therapies.